Navigation Links
Genes signal late-stage laryngeal cancer, poorer outcome
Date:10/7/2009

SAN DIEGO Researchers at Henry Ford Hospital have identified tumor-suppressing genes that may provide a more accurate diagnosis of disease stage and survival for laryngeal cancer patients than current standards.

The study finds genetic abnormalities of the ESR1(estrogen specific receptor 1) gene and the HIC1 (hypermethylated in cancer 1) gene are predictors of late-stage laryngeal cancer and shorter survival, respectively, for patients with the disease.

Study results will be presented Wednesday, Oct. 7 at the American Academy of OtolaryngologyHead & Neck Surgery Foundation Annual Meeting & OTO EXPO.

"These two genes provide some insight into the biology of the tumor," says study senior author Maria J. Worsham, Ph.D., director of research in the Department of Otolaryngology at Henry Ford Hospital. "Loss of gene function as a result of abnormal methylation of promoter regions of tumor suppressor genes can be reversed by drugs that can restore normal gene function, opening the door to other treatment options for patients with laryngeal cancer."

Similar to previous studies on laryngeal cancer, the Henry Ford study also shows that African Americans are more likely to be diagnosed with late-stage laryngeal cancer.

This year alone, the American Cancer Society estimates 12,290 new cases of laryngeal cancer cancers that start in the voice box will be diagnosed.

Following diagnosis, the cancer stage is currently assessed based on tumor size and how far it's spread within the voice box, and whether the cancer has spread to lymph nodes or other organs. The stage (0-4) of the cancer helps health care providers make a prognosis for survival and determine a possible course for treatment.

For the study, Henry Ford researcher and lead author Josena Stephen, M.D., and Dr. Worsham looked at 80 patients with laryngeal squamous cell cancer who were diagnosed between 1996 and 2008. Forty percent of the study group was African American.

Using tissue DNA samples the researchers examined the methylation status of 24 tumor suppressor genes and tested for the presence of the human papilloma virus (HPV). DNA methylation a type of chemical modification of DNA where a methyl group (CH3) can be added (hypermethylation) or removed (hypomethylation) allows the researchers to look for genetic abnormalities within tumor samples.

The study found:

  • Abnormal DNA methylation of ESR1 predicted late stage disease.
  • African Americans are more likely to have advanced stage disease than their Caucasian counterparts, a finding consistent with previous research.
  • Abnormal DNA methylation of HIC1, late stage disease, and vascular invasion were predictors of shorter survival.
  • The median survival for patients in the study group was 4.2 years.
  • HPV was much higher in this group of patients (37 percent), supporting the role of HPV in laryngeal cancer.
  • The majority of patients were either current or past smokers and alcohol users, again confirming the role these factors play in laryngeal cancer.

"When this research crosses from the lab to clinical care, the contribution of specific gene changes will assist in improving the accuracy of cancer staging and length of survival for laryngeal cancer patients," explains Dr. Worsham.

"So if a patient comes in with stage 1, based on current standards, and then we find methylation of ESR1, the patient may have underpinnings of a more aggressive tumor with characteristics that are more in line with a stage 3 or stage 4 diagnosis, refining treatment options."


'/>"/>

Contact: Krista Hopson
khopson1@hfhs.org
313-874-7207
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Researchers identify genes associated with onset age of Parkinsons disease
2. SAGE launches Genes & Cancer
3. Lung cancer risk increases with expression of specific genes
4. Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
5. Two Genes May Determine How Well MS Patients Do
6. Mayo Clinic identifies 2 genes as potential therapeutic targets for multiple sclerosis
7. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results on September 9
8. Benji, Marley or Bo: Three Genes Dictate Dogs Coat
9. Sixteen Genesis HealthCare Centers Receive Prestigious Award for Continuous Quality Improvement in Long Term Care
10. Cardiogenesis Reports Second Quarter 2009 Results
11. ThermoGenesis Announces Launch of Res-Q System; New Device Expands Companys Presence in Bone Marrow Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
(Date:12/8/2016)... ... ... California Senate Bill (SB) 863, signed into law in 2012, may have ... according to CompScope™ Medical Benchmarks for California, 17th Edition , a study by ... payments per claim in California decreased 4 percent in 2013 and then 3 percent ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is in flux. The ... for the mass media launching of story movements to highlight what's most unfair ... unfortunate experiences; such a movement can generate the network power to improve healthcare ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Little Rock, has initiated a charity drive to ... the National Foundation to End Senior Hunger, Arkansas ranks first in senior hunger ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Jefferson County, is announcing the launch of a ... Birmingham. , The number of homeless women and children in Birmingham has grown ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Research and Markets has announced the addition of the ... ... The global chromatography market to grow at a CAGR of 5.42% during ... prepared based on an in-depth market analysis with inputs from industry experts. ... coming years. The report also includes a discussion of the key vendors ...
(Date:12/8/2016)... 2016 According to a ... Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), Type ... Agents), Formulation (Oral, Topical, Parenteral) - Global Forecast ... witnessed healthy growth during the last decade, and ... 4.3% between 2016 and 2021 to reach USD ...
(Date:12/8/2016)... SAN FRANCISCO, Calif. , Dec. 8, 2016 ... nuclease technology to develop novel antiviral therapeutics, today ... M.D., as chief executive officer and a member ... is an incredibly experienced executive with a deep ... said Stephen Quake, D.Phil., founder of Agenovir, co-president ...
Breaking Medicine Technology: